IL311344A - Preparations and methods for the treatment of synoclinopathies - Google Patents

Preparations and methods for the treatment of synoclinopathies

Info

Publication number
IL311344A
IL311344A IL311344A IL31134424A IL311344A IL 311344 A IL311344 A IL 311344A IL 311344 A IL311344 A IL 311344A IL 31134424 A IL31134424 A IL 31134424A IL 311344 A IL311344 A IL 311344A
Authority
IL
Israel
Prior art keywords
antibody
pharmaceutical composition
liquid pharmaceutical
use according
alpha synuclein
Prior art date
Application number
IL311344A
Other languages
English (en)
Hebrew (he)
Inventor
S?DERBERG Josefine NIELSEN
Pekka Kallunki
Louise Buur
Frank Larsen
Henrik Rajesh Kumar Parshad
Anne Sofie Markussen
Mark Cornell Manning
Derrick Spencer Katayama
Magdalena Gauden
John Smith
Original Assignee
H Lundbeck As
S?DERBERG Josefine NIELSEN
Pekka Kallunki
Louise Buur
Frank Larsen
Henrik Rajesh Kumar Parshad
Anne Sofie Markussen
Mark Cornell Manning
Derrick Spencer Katayama
Magdalena Gauden
John Smith
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lundbeck As, S?DERBERG Josefine NIELSEN, Pekka Kallunki, Louise Buur, Frank Larsen, Henrik Rajesh Kumar Parshad, Anne Sofie Markussen, Mark Cornell Manning, Derrick Spencer Katayama, Magdalena Gauden, John Smith filed Critical H Lundbeck As
Publication of IL311344A publication Critical patent/IL311344A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
IL311344A 2021-09-16 2022-09-13 Preparations and methods for the treatment of synoclinopathies IL311344A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP21197120 2021-09-16
PCT/EP2022/075402 WO2023041524A2 (en) 2021-09-16 2022-09-13 Compositions and methods for treating synucleinopathies

Publications (1)

Publication Number Publication Date
IL311344A true IL311344A (en) 2024-05-01

Family

ID=78049153

Family Applications (1)

Application Number Title Priority Date Filing Date
IL311344A IL311344A (en) 2021-09-16 2022-09-13 Preparations and methods for the treatment of synoclinopathies

Country Status (12)

Country Link
US (6) US12077578B2 (cg-RX-API-DMAC7.html)
EP (1) EP4401770A2 (cg-RX-API-DMAC7.html)
JP (1) JP2024534947A (cg-RX-API-DMAC7.html)
KR (1) KR20240055758A (cg-RX-API-DMAC7.html)
CN (1) CN117915952A (cg-RX-API-DMAC7.html)
AR (1) AR127054A1 (cg-RX-API-DMAC7.html)
AU (1) AU2022348798A1 (cg-RX-API-DMAC7.html)
CA (1) CA3230055A1 (cg-RX-API-DMAC7.html)
CL (2) CL2024000753A1 (cg-RX-API-DMAC7.html)
IL (1) IL311344A (cg-RX-API-DMAC7.html)
MX (1) MX2024002970A (cg-RX-API-DMAC7.html)
WO (1) WO2023041524A2 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2019114679A (ru) * 2016-11-15 2020-12-17 Х. Лундбекк А/С Средства, пути применения и способы лечения синуклеопатии
IL311344A (en) 2021-09-16 2024-05-01 H Lundbeck As Preparations and methods for the treatment of synoclinopathies
IL326387A (en) * 2023-09-14 2026-04-01 Hoffmann La Roche Antibody formulation
WO2025186235A1 (en) 2024-03-05 2025-09-12 H. Lundbeck A/S Compositions and methods for treating multiple system atrophy (msa)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2361928T3 (en) * 2003-05-19 2017-07-03 Prothena Biosciences Ltd Truncated fragments of alpha synuclein in Lewy body disease
US10513555B2 (en) * 2013-07-04 2019-12-24 Prothena Biosciences Limited Antibody formulations and methods
CN114717264A (zh) 2014-11-14 2022-07-08 沃雅戈治疗公司 治疗肌萎缩性侧索硬化(als)的组合物和方法
GB201512203D0 (en) 2015-07-13 2015-08-19 Lundbeck & Co As H Agents,uses and methods
WO2017176835A2 (en) * 2016-04-06 2017-10-12 Imago Pharmaceuticals, Inc. Therapeutic antibodies for treatment of neurodegeneration
RU2019114679A (ru) * 2016-11-15 2020-12-17 Х. Лундбекк А/С Средства, пути применения и способы лечения синуклеопатии
JOP20190227A1 (ar) * 2017-03-31 2019-09-30 Biogen Int Neuroscience Gmbh تركيبات وطرق لعلاج اعتلالات السينوكلين
IL311344A (en) 2021-09-16 2024-05-01 H Lundbeck As Preparations and methods for the treatment of synoclinopathies

Also Published As

Publication number Publication date
WO2023041524A3 (en) 2023-05-11
US12351624B2 (en) 2025-07-08
US12358975B2 (en) 2025-07-15
JP2024534947A (ja) 2024-09-26
US20240400661A1 (en) 2024-12-05
EP4401770A2 (en) 2024-07-24
CA3230055A1 (en) 2023-03-23
CL2024003713A1 (es) 2025-04-21
CN117915952A (zh) 2024-04-19
US20240400660A1 (en) 2024-12-05
AU2022348798A1 (en) 2024-03-14
US20240400662A1 (en) 2024-12-05
US12358974B2 (en) 2025-07-15
CL2024000753A1 (es) 2024-09-23
US20240025979A1 (en) 2024-01-25
US20250084156A1 (en) 2025-03-13
WO2023041524A2 (en) 2023-03-23
KR20240055758A (ko) 2024-04-29
US12077578B2 (en) 2024-09-03
MX2024002970A (es) 2024-03-27
US20260217807A1 (en) 2026-07-30
AR127054A1 (es) 2023-12-13

Similar Documents

Publication Publication Date Title
JP7080263B2 (ja) 高濃度の抗vegf抗体を含有する安定状態のタンパク質溶液製剤
TWI761453B (zh) 抗rsv單株抗體配製物
JP2017160208A5 (cg-RX-API-DMAC7.html)
RU2018107725A (ru) Стабильный состав на основе антитела к ifnar1
JP7089121B2 (ja) 高濃度の抗vegf抗体を含有するタンパク質溶液製剤
JP2024534947A5 (cg-RX-API-DMAC7.html)
JP2020506924A5 (cg-RX-API-DMAC7.html)
JP2020063261A (ja) TNFR及びFc領域を含む融合タンパク質の液体製剤
JP7398958B2 (ja) 安定的抗osmr抗体製剤
WO2023006055A1 (en) Anti-pd-1 antibody pharmaceutical composition and use thereof
JP2024515968A5 (cg-RX-API-DMAC7.html)
JP2024538140A5 (cg-RX-API-DMAC7.html)
AU2016344133A1 (en) Anti-Factor D antibody formulations
KR20230009897A (ko) 항-IL-23p19 항체를 포함하는 제제, 이의 제조방법 및 용도
TWI726426B (zh) 包含抗ox40抗體的製劑、其製備方法及其用途
RU2024106395A (ru) Композиции и способы для лечения синуклеинопатий
RU2745814C1 (ru) Водная фармацевтическая композиция левилимаба и ее применение
TWI887362B (zh) 抗內皮脂肪酶抗體之配製物
HK40110786A (en) Anti-rsv monoclonal antibody formulation
HK40093820A (en) Anti-rsv monoclonal antibody formulations
HK40011725B (en) Anti-rsv monoclonal antibody formulation